BGI Americas, headquartered inCambridge,MA, was founded on April 27th, 2010. Supported by BGI and its expertise in advanced sequencing technologies, high quality next-generation sequencing and bioinformatics analysis. BGI Americas has established partnerships and collaborations with leading American academic and government research institutions as well as global biotechnology and pharmaceutical companies to accelerate the application, innovation and development of genomic research.

BGI Americas has created collaborative relations and earned a good reputation with world-class universities, research institutes, and pharmaceutical companies in theAmericas.  Currently, 18 out of the world’s top 20 largest pharmaceutical companies use BGI’s services.  Moreover, BGI Americas is frequently featured in many leading media, including New Your Times, Forbes, BusinessWeek, and Science.  In early 2013, BGI was ranked top4 inthe World’s Top 10 Most Innovative Companies in China by Fast Company, one of the most famous business journals in the United States,for advancing both the science and the business of genetic sequencing and was name to MIT Technology Review’s 2013 50 Disruptive Companies List, which recognizes world’s most innovative companies.

For more information about BGI Americas, please visit

In 2010
April 27, 2010 BGI Americas was founded.
In 2011
Oct 25, 2011 Partnered with Children’s Hospital of Philadelphia, BGI@CHOP conducted large-scale human genome sequencing and bioinformatics analysis at a newly established, state-of-the-art Joint Genome Center at CHOP.
November, 2011  Partnered with UC Davis, BGI@UC Davis established a state-of-the-art BGI sequencing facility BGI@UC Davis Joint Genome Center on the UC Davis Health System campus in Sacramento.
In 2012
August, 2012 BGI Research@Americas was registered in Maryland as BGI’sfirst nonprofit research organization in the Americas.
Sept 27, 2012 The 1st International Conference on Genomics in the Americas (ICG-Americas 2012) was held in Philadelphia, PA. More than 400 participants, including global industry thought leaders, prominent researchers and top policy makers of genomics Industry attended the event.
In 2013
March 18, 2013 Completed the acquisition of Complete Genomics, Inc. (formerly NASDAQ: GNOM), an innovative leader in accurate whole human genomic sequencing.

BGI Americas is in charge of all BGI operations in the Americas.  We provide comprehensive sequencing and bioinformatics services for medical, agricultural and environmental applications. Our team is dedicated to help our customers and partners to achieve their research goals by delivering rapid, high-quality results using a broad array of cost-effective, cutting-edge technologies. We offer a broad range of services including genomics, transcriptomics, epigenomics, proteomics, and bioinformatics on a wide range of samples, including FFPE samples. 

The research branch of BGI established BGI Research@Americas in Maryland in 2012 as BGI’s first nonprofit research organization in the Americas. The institute currently conducts joint-research projects and seeks pubic or private funding. It opens another way for us to collaborate with leading researchers in the Americas for scientific advancement.

Our Lab Facilities in the US

BGI Americas has two joint genome centers in the US – BGI@UC Davis and BGI@CHOP Joint Genome Centers. Both centers are providing sequencing services for clients across Americas.

BGI@CHOP Joint Genome Centers

In November 2011, BGI Americas announced a partnership with Children’s Hospital of Philadelphia, BGI@CHOP, to conduct large-scale human genome sequencing and bioinformatics analysis at a newly established, state-of-the-art Joint Genome Center at CHOP. The partnership focuses initially on the discovery of genes underpinning rare and common pediatric diseases using next-gen sequencing. The center is fully operational and offers sequencing services with ultrafast turnaround time for clients across the Americas.

BGI@CHOP Joint Genome Center

BGI@UC Davis Joint Genome Centers

In October 2011, BGI entered a partnership with University of California, Davis, to establish a state-of-the-art BGI sequencing facility on the UC Davis Health System campus in Sacramento. The new sequencing facility is used to support research initiatives and collaborations and leverages the existing strengths across the Davis and Sacramento campuses concentrating on human and animal health and medicine, food safety and security, biology, and the environment. The center is now accepting samples from clients across the Americas. To learn more, visit

BGI@UC Davis Joint Genome Center

WHITEHOUSE STATION, N.J. and SHENZHEN, China, Sept. 13, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and BGI established a collaboration to focus on the discovery and development of biomarkers and genomic technologies. Under the agreement scientists from Merck and BGI will work closely together to identify and characterize biomarkers with an emphasis on drug discovery, drug development and diagnostics applications across a wide range of therapeutic areas. 

NEW YORK, N.Y., CAMBRIDGE, M.A. and SHENZHEN, CHINA (October 13, 2011) – Autism Speaks, the world’s largest autism science and advocacy organization, and BGI entered into a partnership to create the world’s largest library of sequenced genomes of individuals with autism spectrum disorders (ASD). Using the Autism Speaks Autism Genetic Resource Exchange (AGRE), this collaboration will perform whole genome sequencing on more than 2,000 participating families who have two or more children on the autism spectrum. The data from the 10,000 AGRE participants will enable new research in the genomics of ASD, and significantly enhance the science and technology networks of both Autism Speaks and BGI. In addition, Autism Speaks and BGI will collect and sequence genome samples from individuals in China.

Seattle, WA and Shenzhen, China September 25, 2012 – BGI and the Bill & Melinda Gates Foundation have signed a Memorandum of Understanding (MOU) to form a collaboration on global health and agricultural development with the goal of achieving common objectives in health and agricultural development, and meaningfully contributing to the achievement of one or more of the Millennium Development Goals. The signing ceremony, attended by Dr. Jian Wang, Director and Co-founder of BGI, Dr. Jun Wang, Executive Director, BGI, and Bill Gates of the Gates Foundation, was conducted yesterday outside of Seattle, Washington.

Cambridge, MA and Shenzhen, China, March 21, 2013 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, and BGIentered into a partnership to sequence and publish genomic data from pre-clinical cancer models. This research, which aims to identify and validate recurrent gene mutations that are potential targets for drug therapies, is crucial for the entire oncology drug discovery industry. Consistent with their respective ongoing commitments to open-access research, as well as BGI’s distinguished history of published, collaborative research, H3 and BGI will release the cancer genomic data to the global research community upon completion of data analysis.